Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study

Hirano, Masayuki; Seguchi, Jiro; Yamamura, Masahiro; Narita, Akiko; Okanobu, Hirotaka; Nishikomori, Ryuta; Heike, Toshio; Hosokawa, Mio; Morizane, Yuki; Shiraga, Fumio

Hirano, Masayuki ... (et al.). Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study. Journal of Ophthalmic Inflammation and Infection 2015, 5: 34.

2015-11-21
http://hdl.handle.net/2433/214462

© 2015, Hirano et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study

Masayuki Hirano1*, Jiro Seguchi2, Masahiro Yamamura3, Akiko Narita2, Hirotaka Okanobu4, Ryuta Nishikomori5, Toshio Heike5, Mio Hosokawa1, Yuki Morizane1 and Fumio Shiraga1

Abstract

Background: Cryopyrin-associated periodic syndrome (CAPS) is a group of rare autoinflammatory diseases, and of these, chronic infantile neurologic, cutaneous, and articular/neonatal-onset multisystem inflammatory disease (CINCA/NOMID) syndrome has the most severe phenotype. Canakinumab, a monoclonal antibody that targets interleukin-1β, has been shown to be an effective treatment for resolving systemic inflammation. However, its efficacy for treating ophthalmic symptoms of this disorder remains unclear.

Findings: A 64-year-old female reported episodes of nonpruritic urticaria, fever, aseptic meningitis, and bilateral sensorineural deafness. Her son had experienced similar symptoms. She was initially referred for ophthalmologic treatment for an infectious corneal ulcer. Examination of her right eye by slit lamp biomicroscopy showed diffuse conjunctival injection, corneal infiltrates, a corneal ulcer, and hypopyon. She was therefore treated aggressively with topical and systemic antibiotics in addition to antifungal medications. However, this was ineffective. Genetic analysis detected the heterozygous germline p.Asp303Asn mutation in the NLRP3 gene in both our patient and her son. She was therefore diagnosed with CINCA/NOMID syndrome based on her clinical manifestations. All of the patient’s physical and ophthalmic symptoms were resolved within a few days after the initiation of canakinumab treatment. During an 18-month follow-up period, no adverse events or severe infections were observed.

Conclusions: Our case report indicates that canakinumab is effective not only for the treatment of systemic inflammation but also for treating ophthalmic involvement, such as recurrent stromal keratitis and anterior uveitis.

Keywords: Cryopyrin-associated periodic syndrome, Chronic infantile neurologic, Cutaneous and articular/neonatal-onset multisystem inflammatory disease syndrome, Canakinumab, Stromal keratitis, Uveitis

Findings

Background

Cryopyrin-associated periodic syndrome (CAPS) is an autoinflammatory disorder caused by heterozygous mutations in the NLRP3 gene and include three distinct conditions, namely familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and chronic infantile neurologic, cutaneous, and articular (also known as neonatal-onset multisystem inflammatory disease) (chronic infantile neurologic, cutaneous, and articular/neonatal-onset multisystem inflammatory disease (CINCA/NOMID)) syndrome [1–5]. Gain-of-function mutations in NLRP3 result in the excessive production of the potent proinflammatory cytokine interleukin-1β (IL-1β), thereby evoking the autoimmune manifestations of CAPS [6–8]. CINCA/NOMID syndrome is the most severe...
The eye manifestations are pleiotropic in patients with CINCA/NOMID syndrome, with inflammation involving the cornea, sclera, anterior chamber, vitreous, retina, and optic disc. Canakinumab, a fully humanized monoclonal antibody that selectively blocks IL-1β, has been shown to be an effective treatment for CINCA/NOMID syndrome. However, the efficacy of canakinumab in treating its ophthalmic manifestations remains unclear.

Here, we describe a case of an adult female with CINCA/NOMID syndrome-related stromal keratitis and uveitis, which was successfully treated with canakinumab.

**Case presentation**

A 64-year-old female was referred to our department for the treatment of an infectious corneal ulcer. She reported experiencing daily episodes of urticaria-like rashes, fevers, and arthralgia since birth. She also had a history of meningitis, which showed no evidence of infection and did not respond to antibiotic treatment, and bilateral sensorineural deafness since high school. The patient had been evaluated for collagen diseases many times at other hospitals, but no disease-specific autoantibodies had been detected. Her detailed ophthalmic history was unclear. Her family history was significant in that her son had displayed similar symptoms from birth that had been treated with corticosteroids and immunosuppressants.

At the patient’s initial visit, a clinical examination confirmed the presence of a rash on her body with a saddle nose and clubbed fingers. Biological inflammatory markers, including the white blood cell count and C-reactive protein (CRP) level, were high. The patient’s visual acuity was 20/400 in the right eye and 20/22 in the left eye, and the intraocular pressure was 11 mmHg in both eyes. Slit lamp biomicroscopy of the right pseudophakic eye showed diffuse conjunctival injection, pterygium-like corneal invasion of the conjunctival tissue, and the presence of corneal infiltrates with epithelial erosion (Fig. 1a). Marked cell and flare with hypopyon were also present in the anterior chamber of the right eye. An opening existed from previous laser iridectomy. The details of the right fundus were obscured by corneal opacity and anterior inflammation.

Although the anterior segment of the left pseudophakic eye was normal, a fundus examination showed a pale optic disc, sheathing of the retinal arteries, and yellowish deposits in the posterior pole (Fig. 1b, c).

Based on the observations above, we considered the possibility of a corneal bacterial and/or fungal infection. The patient was therefore treated with topical and systemic antibiotics (eyedrops containing 0.5 % levofloxacin, 0.3 % gatifloxacin, 0.5 % cefmenoxime, and 0.3 % gentamicin and intravenous flomoxef at 2 g/day) and...
also with antifungal drugs (1% pimaricin ointment and oral itraconazole at 200 mg/day). She received these medications as well as topical corticosteroid therapy (0.1% betamethasone and 0.1% fluorometholone eyedrops) for 9 months. However, this did not completely resolve the problem and repeated exacerbations of anterior inflammation with ulcerative keratitis continued. During the course of this treatment, we carried out microbiological investigations of corneal scrapes, virological investigations for varicella zoster, herpes simplex virus, and cytomegalovirus in the aqueous humor and tests for HLA-B51. However, all tests were negative. During this period, the patient experienced one episode of aseptic meningitis (Fig. 2). In addition, the urticarial rash on her body persisted and her CRP level remained elevated.

The presence of the urticaria-like rash, fever, arthralgia, and both her past history and her family history led us to consider a CAPS diagnosis. Therefore, a genetic analysis was carried out, and this detected a heterozygous, germline p.Asp303Asn mutation in the NLRP3 gene in both the patient and her son, confirming a diagnosis of CAPS. Based on her severe physical and ophthalmic manifestations, including chronic meningitis and posterior segment involvement in the left eye, a diagnosis of CINCA/NOMID syndrome was made. The patient was therefore started on a course of 150 mg canakinumab (Ilaris; Novartis Pharma AG, Basel, Switzerland) given subcutaneously once every 6 weeks. All of the patient’s physical symptoms (rash, arthralgia, aseptic meningitis, and fever) and ophthalmic symptoms (conjunctival injection, ulcerative keratitis, anterior chamber inflammation, and hypopyon) resolved within a few days. In addition, the patient’s CRP level normalized and stabilized (Fig. 2).

After the anterior inflammation had resolved, we conducted a fundus examination, which showed that the right eye was more severely affected than the left eye, with a pale optic disc, peripapillary sheath-like fibrosis involving the retinal vessels, and yellowish deposits in the mid-periphery (Fig. 3a, b). Spectral-domain optical coherence tomography (Cirrus; Carl Zeiss Meditec Inc., Dublin, CA) showed an intact ellipsoid zone and drusen-like subretinal deposits internal to the retinal pigment epithelium (Fig. 3c). At the patient’s last visit, which was 18 months after the first treatment with canakinumab, her visual acuity was 20/66 in the right eye and 20/20 in the left eye and slit lamp biomicroscopy showed no sign of anterior inflammation in the right eye. No adverse events had been documented during the follow-up period.

**Discussion**

In this report, we have described a case of CINCA/NOMID syndrome-related stromal keratitis and uveitis in an adult female, which was successfully treated with canakinumab. To the best of our knowledge, this is the first report of CINCA/NOMID syndrome, which describes the ophthalmic findings before and after the canakinumab treatment in detail. In most of the previous reports describing the efficacy of canakinumab in patients with CAPS, conjunctivitis has been the only end point used to assess ocular manifestations [13, 15]. Therefore, the efficacy of canakinumab for a variety of ophthalmic symptoms had remained unclear. In the patient we have described in this report, we found that canakinumab therapy led to a marked improvement, not only in systemic inflammation but also in ophthalmic manifestations such as recurrent stromal keratitis and anterior uveitis. We were surprised that the subcutaneous injection of canakinumab resolved the ophthalmic inflammation so dramatically, in spite of the presence of blood-retina and blood-aqueous barriers in the eye. Canakinumab has been reported to induce adverse events, such as nasopharyngitis, upper respiratory infections, and gastroenteritis, presumably due to the effects of blocking the actions of the proinflammatory cytokine IL-1β [13, 15]. However, no side effects were observed during the follow-up period in this case. Further observation will be needed to check the long-term efficacy of canakinumab.
This case indicates that it is important to make a diagnosis and start treatment with canakinumab as early as possible to prevent irreversible ocular complications. In our patient, the visual acuity of the right eye did not completely recover, as the delay in diagnosis resulted in post-inflammatory optic disc atrophy and stromal opacification. It has been only 13 years since the mutation of CIAS1 was discovered in CAPS patient. Although the discovery has made much progress in pathophysiologic and therapeutic understanding of CAPS, clear diagnostic criteria have not been yet established. In addition, CAPS is a very rare disease; for example, CINCA/NOMID syndrome has a prevalence of 1/4,000,000 in Japan [16]. These conditions can cause our lack of awareness of the disease, resulting in delayed diagnosis and treatment. We think it is important to consider CAPS including CINCA/NOMID syndrome in the differential diagnosis for patients who present with periodic fever, urticarial-like rashes, meningitis, articular manifestations, and ocular inflammation.

In conclusion, our case report indicates canakinumab is effective in CINCA/NOMID syndrome, not only for systemic inflammation but also for ocular involvement, such as recurrent stromal keratitis and anterior uveitis. Further prospective studies will be required to determine the efficacy of canakinumab, including as many patients as possible with this rare disease.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
CAPS: cryopyrin-associated periodic syndrome; CINCA: chronic infantile neurologic, cutaneous and articular; CRP: C-reactive protein; IL-1β: interleukin-1β; NOMID: neonatal-onset multisystem inflammatory disease.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
MH, JS, MY, MHo, and YM designed and conducted the study. MH, JS, MY, AN, and HO provided clinical care. MY, RN, and TH conducted the genetic test. MH, MHo, and YM wrote the article. JS, MY, AN, HO, RN, TH, and FS critically revised the article and gave it their final approval. All authors read and approved the final manuscript.

Authors' information
MH is a retinal fellow at Okayama University Hospital. JS is a surgical retina specialist at Okayama Saiseikai General Hospital. MY is a specialist of collagen diseases at Okayama Saiseikai General Hospital. AN is a glaucoma specialist at Okayama Saiseikai General Hospital. HO is a clinical geneticist at Kurashiki Medical Center. RN is an associate professor and specialist of pediatric immunology at Okayama University Hospital. TH is a professor and specialist of pediatric immunology at Kyoto University Hospital. MHo is an assistant professor and medical retina specialist at Okayama University Hospital. YM is a lecturer and surgical retina specialist at Okayama University Hospital at Okayama University Hospital. FS is a professor and surgical retina specialist at Okayama University Hospital.

Acknowledgements
The authors have no support from a funding body.

Fig. 3 Ophthalmic findings in the right eye after canakinumab therapy. a Anterior inflammation (conjunctival injection, ulcerative keratitis, anterior chamber inflammation, and hypopyon) remained resolved 6 months after the initiation of canakinumab therapy. b Fundus examination of the right eye showed a pale optic disc with peripapillary sheath-like fibrosis involving the retinal vessels (arrowhead) and yellowish deposits in the posterior pole (arrows). c Spectral-domain optical coherence tomography showed intact ellipsoid zone and drusen-like subretinal deposits (arrows) internal to the retinal pigment epithelium.
Author details
1Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
2Department of Ophthalmology, Okayama Saiseikai General Hospital, Okayama, Japan. Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan. 3Department of Ophthalmology, Kurashiki Medical Center, Kurashiki, Japan. 4Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Received: 27 August 2015 Accepted: 13 November 2015

References
1. Feldmann J, Prieur A-M, Quartier P et al (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71:198–203
2. Hassink SG, Goldsmith DP (1983) Neonatal onset multisystem inflammatory disease. Arthritis Rheum 26:668–673
3. Hawkins PN, Lachmann HJ, Agana E, McDermott MF (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50:607–612. doi:10.1002/art.20033
4. Lachmann HJ, Lowe P, Felix SD et al (2009) In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 206:1029–1036. doi:10.1084/jem.20082481
5. Aksentijevich I, Nowak M, Mallah M et al (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46:3340–3348. doi:10.1002/art.10688
6. Dinarello CA (2007) Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. Arthritis Rheum 56:2817–2822. doi:10.1002/art.22841
7. Neven B, Prieur A-M, Quartier Dit Maire P (2008) Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 4:481–489. doi:10.1038/ncprheum0874
8. Gattorno M, Tassi S, Carta S et al (2007) Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CAS1 mutations. Arthritis Rheum 56:3138–3148. doi:10.1002/art.22842
9. Prieur AM, Griscelli C, Lampert F et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 66:57–68
10. Inamo Y, Kin H, Fujita Y et al (1994) Chronic, infantile, neurological, cutaneous and articular syndrome in Japan; two case reports. Clin Exp Rheumatol 12:447–449
11. Dolfius H, Hafner R, Hofmann HM et al (2000) Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol 118:1386–1392
12. Hoffman HM, Patel DD (2004) Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum 50:345–349. doi:10.1002/art.20032
13. Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70:2095–2102. doi:10.1136/ard.2011.152728
14. Goldbach-Mansky R, Dailey NJ, Canna SW et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581–592. doi:10.1056/NEJMoa055137
15. Imagawa T, Nishikomi R, Takada H et al (2013) Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 31:302–309
16. Aksentijevich I (2007) Clinical observation of autoinflammatory diseases. Nihon Rinsho Meneki Gakkai Kaishi 30:63–67

Submit your manuscript to a SpringerOpen journal and benefit from:
▸ Convenient online submission
▸ Rigorous peer review
▸ Immediate publication on acceptance
▸ Open access: articles freely available online
▸ High visibility within the field
▸ Retaining the copyright to your article

Submit your next manuscript at springeropen.com